Challenges and Opportunities in Tuberculosis Control: Innovations in Diagnosis and Treatment

Challenges and Opportunities in Tuberculosis Control: Innovations in Diagnosis and Treatment

Product not yet rated

Tuberculosis remains one of the world’s leading infectious disease challenges, requiring ongoing innovation in both diagnosis and treatment. This session examines the current landscape of TB control, focusing on the barriers that continue to impact early detection, effective treatment, and global eradication efforts.

Attendees will gain insight into cutting-edge diagnostic tools designed to improve accuracy and speed, as well as new and evolving treatment regimens aimed at enhancing patient outcomes and addressing drug-resistant strains. The session will also explore broader public health considerations, including access to care, implementation challenges, and opportunities for scalable solutions.

By the end of this session, participants will have a clearer understanding of where TB control stands today—and where innovation is driving meaningful progress for the future.

David Forty, DDS, MS, MSD

Professor

University of Georgia

Dr. David Paquette received his DDS in 1979 and his MS in Pediatric Dentistry in 1983 from the UNC School of Dentistry. His Master's thesis in pediatric dentistry won the AAPD research award. He obtained his specialty certificate in orthodontics and MSD in orthodontics in January 1990 from St Louis Univ. His Master's thesis in orthodontics won the Milo Hellman award in 1991. Dr. Paquette has written and published multiple articles for scientific journals and has authored two textbook chapters. He retired from private practice in 2021 and currently holds the position of Lead Clinical Advisor at Henry Schein Orthodontics.

Key:

Complete
Failed
Available
Locked
Recorded Conference Session
Open to view video.
Open to view video. This presentation highlights recent advancements in immunotherapy for melanoma, focusing on novel treatment approaches and combination strategies. We discuss the mechanisms of action of immunotherapeutic agents, clinical trial data, and emerging biomarkers for predicting treatment response.
Survey
3 Questions
3 Questions Rate 1-5